Mylan (MYL) is going to start selling a generic version of its EpiPen allergy treatment at a more than 50% discount. The treatment will be available at pharmacies starting next week. Mylan's announcement comes one day after 20 states filed a lawsuit against Mylan and other generic drugmakers over prices, according to Reuters. The much criticized company has been under investigation by the US government and its CEO had to testify before Congress over big price increases for its Epipen, priced at about $600 for a two-pack.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.